155 related articles for article (PubMed ID: 38603771)
1. Predictors and Clinical Characteristics of Relapses in LGI1-Antibody Encephalitis.
Campetella L; Farina A; Villagrán-García M; Villard M; Benaiteau M; Timestit N; Vogrig A; Picard G; Rogemond V; Psimaras D; Rafiq M; Chanson E; Marchal C; Goncalves D; Joubert B; Honnorat J; Muñiz-Castrillo S
Neurol Neuroimmunol Neuroinflamm; 2024 May; 11(3):e200228. PubMed ID: 38603771
[TBL] [Abstract][Full Text] [Related]
2. [Clinical analysis of relapsing anti-N-methyl-D-aspartate receptor encephalitis].
Hongzhi G; Weize K; Bin P; Yan H; Qiang L; Yuan J; Qing L; Hang S; Haitao R; Yicheng Z; Dawei S; Liying C
Zhonghua Yi Xue Za Zhi; 2015 Apr; 95(13):996-1001. PubMed ID: 26506710
[TBL] [Abstract][Full Text] [Related]
3. [Clinical features and outcomes in relapsing and monophasic patients with anti-leucine-rich glioma-inactivated 1 encephalitis].
Li JM; Ma XR; Peng T; Li JH; Lu H
Zhonghua Yi Xue Za Zhi; 2020 Jul; 100(25):1947-1951. PubMed ID: 32629594
[No Abstract] [Full Text] [Related]
4. CHI3L1 in the CSF is a potential biomarker for anti-leucine-rich glioma inactivated 1 encephalitis.
Li J; Li H; Wang Y; Zhao X; Wang S; Li L
Front Immunol; 2022; 13():1071219. PubMed ID: 36685530
[TBL] [Abstract][Full Text] [Related]
5. Neurofunctional outcomes in patients with anti-leucine-rich glioma inactivated 1 encephalitis.
Chen W; Wang M; Gao L; Huang Z; Lin Y; Xue Q; Liu G; Zhang Y; Su Y
Acta Neurol Scand; 2021 Dec; 144(6):632-639. PubMed ID: 34314015
[TBL] [Abstract][Full Text] [Related]
6. Analysis of relapses in anti-NMDAR encephalitis.
Gabilondo I; Saiz A; Galán L; González V; Jadraque R; Sabater L; Sans A; Sempere A; Vela A; Villalobos F; Viñals M; Villoslada P; Graus F
Neurology; 2011 Sep; 77(10):996-9. PubMed ID: 21865579
[TBL] [Abstract][Full Text] [Related]
7. Clinical Course and Features of Seizures Associated With LGI1-Antibody Encephalitis.
Smith KM; Dubey D; Liebo GB; Flanagan EP; Britton JW
Neurology; 2021 Sep; 97(11):e1141-e1149. PubMed ID: 34233939
[TBL] [Abstract][Full Text] [Related]
8. Neurological, psychiatric, and sleep investigations after treatment of anti-leucine-rich glioma-inactivated protein 1 (LGI1) encephalitis in Spain: a prospective cohort study.
Muñoz-Lopetegi A; Guasp M; Prades L; Martínez-Hernández E; Rosa-Justícia M; Patricio V; Armangué T; Rami L; Borràs R; Castro-Fornieles J; Compte A; Gaig C; Santamaria J; Dalmau J;
Lancet Neurol; 2024 Mar; 23(3):256-266. PubMed ID: 38365378
[TBL] [Abstract][Full Text] [Related]
9. Mycophenolate mofetil reduces the risk of relapse in anti-leucine-rich glioma-inactivated protein 1 encephalitis: a prospective observational cohort study.
Liu M; Xu X; Fan S; Ren H; Zhao Y; Guan H
Neurol Sci; 2024 Jan; 45(1):253-260. PubMed ID: 37580515
[TBL] [Abstract][Full Text] [Related]
10. LGI1 antibody-associated encephalitis without evidence of inflammation in CSF and brain MRI.
Jia Y; Wang H; Zhang M; Wei M; Huang Z; Ye J; Liu A; Wang Y
Acta Neurol Belg; 2023 Jun; 123(3):849-856. PubMed ID: 35527332
[TBL] [Abstract][Full Text] [Related]
11. Clinical features of anti-leucine-rich glioma-inactivated 1 encephalitis in northeast China.
Zhao Q; Sun L; Zhao D; Chen Y; Li M; Lu Y; Li G; Lin W
Clin Neurol Neurosurg; 2021 Apr; 203():106542. PubMed ID: 33706063
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics, long-term functional outcomes and relapse of anti-LGI1/Caspr2 encephalitis: a prospective cohort study in Western China.
Guo K; Liu X; Lin J; Gong X; Li A; Liu Y; Zhou D; Hong Z
Ther Adv Neurol Disord; 2022; 15():17562864211073203. PubMed ID: 35069805
[TBL] [Abstract][Full Text] [Related]
13. Prolonged Corticosteroids Without Maintenance Immunotherapy for Treatment of Anti-LGI1 Encephalitis: Analysis of Outcomes and Relapse Rate.
Alkabie S; Budhram A
Neurol Neuroimmunol Neuroinflamm; 2023 May; 10(3):. PubMed ID: 37015827
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of Persistent CSF Antibodies at 12 Months in Anti-NMDAR Encephalitis.
Ciano-Petersen NL; Robert M; Muñiz-Castrillo S; Wucher V; Klich A; Vogrig A; Villagrán García M; Farina A; Goncalves D; Picard G; Rogemond V; Joubert B; Oliver-Martos B; Serrano-Castro PJ; Maucort-Boulch D; Honnorat J
Neurol Neuroimmunol Neuroinflamm; 2023 Jul; 10(4):. PubMed ID: 37147137
[TBL] [Abstract][Full Text] [Related]
15. Relapses of Anti-NMDAR, Anti-GABABR and Anti-LGI1 Encephalitis: A Retrospective Cohort Study.
Zhong R; Chen Q; Zhang X; Zhang H; Lin W
Front Immunol; 2022; 13():918396. PubMed ID: 35757705
[TBL] [Abstract][Full Text] [Related]
16. Clinical Features, Immunotherapy, and Outcomes of Anti-Leucine-Rich Glioma-Inactivated-1 Encephalitis.
Huang X; Fan C; Gao L; Li L; Ye J; Shen H
J Neuropsychiatry Clin Neurosci; 2022; 34(2):141-148. PubMed ID: 34794327
[TBL] [Abstract][Full Text] [Related]
17. Clinical Features and Long-Term Outcomes of Anti-Leucine-Rich Glioma-Inactivated 1 Encephalitis: A Multi-Center Study.
Qiao S; Wu HK; Liu LL; Wang ML; Zhang RR; Han T; Liu XW
Neuropsychiatr Dis Treat; 2021; 17():203-212. PubMed ID: 33531809
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics and short-term prognosis of LGI1 antibody encephalitis: a retrospective case study.
Li W; Wu S; Meng Q; Zhang X; Guo Y; Cong L; Cong S; Zheng D
BMC Neurol; 2018 Jul; 18(1):96. PubMed ID: 29980179
[TBL] [Abstract][Full Text] [Related]
19. Clinical features of 28 cases of anti
Feng J; Li J; Xie Y; Lü Y; Bi F; Zhou J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):386-396. PubMed ID: 37164922
[TBL] [Abstract][Full Text] [Related]
20. Autoimmune encephalitis associated with voltage-gated potassium channels-complex and leucine-rich glioma-inactivated 1 antibodies - a national cohort study.
Celicanin M; Blaabjerg M; Maersk-Moller C; Beniczky S; Marner L; Thomsen C; Bach FW; Kondziella D; Andersen H; Somnier F; Illes Z; Pinborg LH
Eur J Neurol; 2017 Aug; 24(8):999-1005. PubMed ID: 28544133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
